<DOC>
	<DOCNO>NCT02487199</DOCNO>
	<brief_summary>This study evaluate efficacy safety ombitasvir/paritaprevir/ritonavir without dasabuvir adult genotype 1a genotype 4 hepatitis C infect participant severe kidney impairment end-stage kidney disease .</brief_summary>
	<brief_title>Ombitasvir/Paritaprevir/Ritonavir With Without Dasabuvir Adults With Genotype 1a Genotype 4 Chronic Hepatitis C Virus ( HCV ) Infection , With Severe Kidney Impairment End Stage Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic hepatitis C , genotype 1a infection genotype 4 infection ( HCV RNA level great 1,000 IU/mL Screening ) . Females must postmenopausal , nonchild bear potential practicing specific form birth control . Chronic kidney disease stage 4 stage 5 . Females pregnant breastfeed Positive screen hepatitis B Surface antigen antiHuman Immunodeficiency virus antibody HCV genotype perform screen unable genotype coinfection HCV genotype , mixed genotype . Abnormal laboratory test Current enrollment another investigational study Prior treatment direct act antiviral agent ( DAA ) contain regimen exception interferon pegylated interferon without ribavirin Current treatment direct act antiviral agent ( DAA ) contain regimen Any evidence liver cirrhosis liver cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hepatitis C infection</keyword>
	<keyword>interferon</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>treatment experience</keyword>
	<keyword>severe kidney disease</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>